Why is Kaposi’s sarcoma-associated herpesvirus not ubiquitous in the human population?

By Bagni Rachel   Whitby Denise  

Future Virology, Vol. 2, Iss. 3, 2007-05 ,pp. : 243-246

Future Medicine

Access to resources Recommend Favorite

African ancestry and innate immunity contribute to the incidence of multicentric Castleman’s disease in HIV-1/Kaposi’s sarcoma herpesvirus-coinfected individuals

By Westrop Samantha J   Lagos Dimitrios   Boshoff Chris   Bower Mark   Imami Nesrina  

Future Virology, Vol. 7, Iss. 7, 2012-07 ,pp. : 729-734

Future Medicine

Access to resources Recommend Favorite

Viral Latent Proteins as Targets for Kaposi's Sarcoma and Kaposi's Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma

By  

Current Drug Targets - Infectious Disorders, Vol. 3, Iss. 2, 2003-06 ,pp. : 129-135

Bentham Science Publishers

Access to resources Recommend Favorite

Novel pharmacological therapies for the treatment of AIDS-related Kaposi’s sarcoma

By Cattelan Anna Maria   Trevenzoli Marco   Aversa Savina Maria Lucia  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 5, 2004-05 ,pp. : 501-513

Informa Healthcare

Access to resources Recommend Favorite

HAART is the centre of graduated systemic treatment of AIDS-associated Kaposi's sarcoma

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 8, 2005-08 ,pp. : 14-17

Adis International

Access to resources Recommend Favorite